Multiple Sclerosis Journal - October 2017 - 1452

Multiple Sclerosis Journal 23(11)
101. Correale J and Fiol M. Chitinase effects on immune
cell response in neuromyelitis optica and multiple
sclerosis. Mult Scler 2011; 17(5): 521-531.
102. Bonneh-Barkay D, Bissel SJ, Kofler J, et al. Astrocyte
and macrophage regulation of YKL-40 expression
and cellular response in neuroinflammation. Brain
Pathol 2012; 22(4): 530-546.
103. Bonneh-Barkay D, Wang G, Starkey A, et al.
In vivo CHI3L1 (YKL-40) expression in astrocytes
in acute and chronic neurological diseases.
J Neuroinflammation 2010; 7: 34.
104. Verbeek MM, Notting EA, Faas B, et al. Increased
cerebrospinal fluid chitotriosidase index in patients
with multiple sclerosis. Acta Neurol Scand 2010;
121(5): 309-314.
105. Hinsinger G, Galeotti N, Nabholz N, et al. Chitinase
3-like proteins as diagnostic and prognostic
biomarkers of multiple sclerosis. Mult Scler 2015;
21(10): 1251-1261.
106. Stoop MP, Singh V, Stingl C, et al. Effects of
natalizumab treatment on the cerebrospinal fluid
proteome of multiple sclerosis patients. J Proteome
Res 2013; 12(3): 1101-1107.
107. Rodrigues LR, Teixeira JA, Schmitt FL, et al.
The role of osteopontin in tumor progression and
metastasis in breast cancer. Cancer Epidemiol
Biomarkers Prev 2007; 16(6): 1087-1097.
108. Mazzali M. Osteopontin - A molecule for all seasons.
QJM 2002; 95(1): 3-13.
109. Ashkar S, Weber GF, Panoutsakopoulou V, et al.
Eta-1 (osteopontin): An early component of type-1
(cell-mediated) immunity. Science 2000; 287(5454):
860-864.
110. Shinohara ML, Kim J-H, Garcia VA, et al.
Engagement of the type I interferon receptor on
dendritic cells inhibits T helper 17 cell development:
Role of intracellular osteopontin. Immunity 2008;
29(1): 68-78.
111. Steinman L. A molecular trio in relapse and remission
in multiple sclerosis. Nat Rev Immunol 2009; 9(6):
440-447.

Visit SAGE journals online
journals.sagepub.com/
home/msj

SAGE journals

1452

112. Chowdhury SA, Lin J and Sadiq SA. Specificity and
correlation with disease activity of cerebrospinal fluid
osteopontin levels in patients with multiple sclerosis.
Arch Neurol 2008; 65(2): 232-235.
113. Braitch M, Nunan R, Niepel G, et al. Increased
osteopontin levels in the cerebrospinal fluid of

patients with multiple sclerosis. Arch Neurol 2008;
65(5): 633-635.
114. Börnsen L, Khademi M, Olsson T, et al. Osteopontin
concentrations are increased in cerebrospinal fluid
during attacks of multiple sclerosis. Mult Scler 2011;
17(1): 32-42.
115. Vogt MHJ, Lopatinskaya L, Smits M, et al. Elevated
osteopontin levels in active relapsing-remitting
multiple sclerosis. Ann Neurol 2003; 53(6): 819-822.
116. Vogt MHJ, Floris S, Killestein J, et al. Osteopontin
levels and increased disease activity in relapsingremitting multiple sclerosis patients. J Neuroimmunol
2004; 155(1-2): 155-160.
117. Comabella M, Pericot I, Goertsches R, et al.
Plasma osteopontin levels in multiple sclerosis.
J Neuroimmunol 2005; 158(1-2): 231-239.
118. Shimizu Y, Ota K, Ikeguchi R, et al. Plasma
osteopontin levels are associated with disease
activity in the patients with multiple sclerosis and
neuromyelitis optica. J Neuroimmunol 2013;
263(1-2): 148-151.
119. Runia TF, van Meurs M, Nasserinejad K, et al. No
evidence for an association of osteopontin plasma
levels with disease activity in multiple sclerosis.
Mult Scler 2014; 20(12): 1670-1671.
120. Kivisäkk P, Healy BC, Francois K, et al. Evaluation
of circulating osteopontin levels in an unselected
cohort of patients with multiple sclerosis: Relevance
for biomarker development. Mult Scler 2014; 20(4):
438-444.
121. Iaffaldano P, Ruggieri M, Viterbo RG, et al. The
improvement of cognitive functions is associated
with a decrease of plasma Osteopontin levels in
Natalizumab treated relapsing multiple sclerosis.
Brain Behav Immun 2014; 35: 176-181.
122. Khademi M, Bornsen L, Rafatnia F, et al. The
effects of natalizumab on inflammatory mediators in
multiple sclerosis: Prospects for treatment-sensitive
biomarkers. Eur J Neurol 2009; 16(4): 528-536.
123. Kuhle J, Barro C, Andreasson U, et al. Comparison
of three analytical platforms for quantification of the
neurofilament light chain in blood samples: ELISA,
electrochemiluminescence immunoassay and Simoa.
Clin Chem Lab Med 2016; 54(10): 1655-1661.
124. Westbrook JA, Noirel J, Brown JE, et al. Quantitation
with chemical tagging reagents in biomarker studies.
Proteomics Clin Appl 2015; 9(3-4): 295-300.

journals.sagepub.com/home/msj
https://journals.sagepub.com/home/msj https://journals.sagepub.com/home/msj https://journals.sagepub.com/home/msj
Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017
